GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » Debt-to-EBITDA

ENDRA Life Sciences (ENDRA Life Sciences) Debt-to-EBITDA : -0.07 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ENDRA Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil. ENDRA Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.19 Mil. ENDRA Life Sciences's annualized EBITDA for the quarter that ended in Dec. 2023 was $-5.59 Mil. ENDRA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ENDRA Life Sciences's Debt-to-EBITDA or its related term are showing as below:

NDRA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.55   Med: -0.06   Max: -0.04
Current: -0.04

During the past 10 years, the highest Debt-to-EBITDA Ratio of ENDRA Life Sciences was -0.04. The lowest was -0.55. And the median was -0.06.

NDRA's Debt-to-EBITDA is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.8 vs NDRA: -0.04

ENDRA Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for ENDRA Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENDRA Life Sciences Debt-to-EBITDA Chart

ENDRA Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.06 -0.06 -0.04 -0.04

ENDRA Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.04 -0.04 -0.04 -0.07

Competitive Comparison of ENDRA Life Sciences's Debt-to-EBITDA

For the Diagnostics & Research subindustry, ENDRA Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENDRA Life Sciences's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's Debt-to-EBITDA falls into.



ENDRA Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ENDRA Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.202 + 0.192) / -10.245
=-0.04

ENDRA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.202 + 0.192) / -5.588
=-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


ENDRA Life Sciences  (NAS:NDRA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


ENDRA Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


ENDRA Life Sciences (ENDRA Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
Michael Milos Thornton officer: Chief Technology Officer 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman director C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon director, officer: Chief Executive Officer 430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova officer: Senior Director, Finance 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti officer: Chief Commercial Officer 10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells officer: Chief Financial Officer 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc 10 percent owner 9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad 10 percent owner 1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir director 3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105